MK-1022-011-00: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: About the safety and how well people tolerate of patritumab deruxtecan How many people have the cancer respond (get smaller or go away) to treatment
Why this Research Matters
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: About the safety and how well people tolerate of patritumab deruxtecan How many people have the cancer respond (get smaller or go away) to treatment
Who can Participate
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. ClinicalTrials.gov to learn more about this study. https://clinicaltrials.gov/study/NCT06596694?term=NCT06596694&rank=1
Study ID
Protocol Number: 24-1883
More information available at ClinicalTrials.gov: NCT06596694
Meet the Team
Principal Investigator